SAFGANDO Trademark

Trademark Overview


On Monday, January 29, 2024, a trademark application was filed for SAFGANDO with the United States Patent and Trademark Office. The USPTO has given the SAFGANDO trademark a serial number of 98381206. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, March 25, 2025. This trademark is owned by Renibus Therapeutics, Inc.. The SAFGANDO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention of heart and chest conditions, diseases, and disorders; pharmaceutical products for the prevention of cardiothoracic conditions, diseases, and disorders; pharmaceutical preparations for protecting against organ damage; pharmaceutical preparations for protecting against organ damage following organ transplant; pharmaceutical preparations for lowering the risks associated with cardiac surgery; pharmaceutical preparations for lowering the risks associated with cardiac surgery, namely, aortic aneurysm, atrial fibrillation, left ventricular assist devices, and transcatheter aortic valve replacement
safgando

General Information


Serial Number98381206
Word MarkSAFGANDO
Filing DateMonday, January 29, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, March 25, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 28, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention of heart and chest conditions, diseases, and disorders; pharmaceutical products for the prevention of cardiothoracic conditions, diseases, and disorders; pharmaceutical preparations for protecting against organ damage; pharmaceutical preparations for protecting against organ damage following organ transplant; pharmaceutical preparations for lowering the risks associated with cardiac surgery; pharmaceutical preparations for lowering the risks associated with cardiac surgery, namely, aortic aneurysm, atrial fibrillation, left ventricular assist devices, and transcatheter aortic valve replacement

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 29, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRenibus Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouthlake, TX 76092

Party NameRenibus Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouthlake, TX 76092

Trademark Events


Event DateEvent Description
Monday, January 29, 2024NEW APPLICATION ENTERED
Tuesday, May 28, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 23, 2024ASSIGNED TO EXAMINER
Thursday, January 2, 2025EXAMINER'S AMENDMENT ENTERED
Thursday, January 2, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 2, 2025EXAMINERS AMENDMENT E-MAILED
Friday, August 30, 2024NON-FINAL ACTION E-MAILED
Friday, August 30, 2024NON-FINAL ACTION WRITTEN
Friday, August 30, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 2, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, January 2, 2025EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 22, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 28, 2025PUBLISHED FOR OPPOSITION
Tuesday, January 28, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 25, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT